NeutroGen Therapeutics Receives Pre-Seed Investment from IBB Ventures

NeutroGen Therapeutics is pleased to announce that the company has received a pre-seed investment from IBB Ventures through its new B# (be sharp) program. According to IBB Ventures, NeutroGen is the first startup to receive funding under this initiative.

The funding will support the development of NeutroGen's platform for laboratory-produced allogeneic neutrophils, a novel cell therapy approach designed to address severe neutropenia and treatment-resistant infections.

"We are excited to work with IBB Ventures and the B# program as we take the first steps toward clinical validation of our technology," said Felix Jensen-Dietrich, Co-CEO of NeutroGen Therapeutics.

For further details, please read the official IBB Ventures press release: https://www.ibbventures.de/de/news/neutrogen-bsharp